Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 2/20 | 0.47 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | CLK3 | P49761 | 3/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.40 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701778 | 0.77 | EGFR (0.43) | FYNCYP17A1CYP11B1CYP11B2CDK1 | |
| SCHEMBL3699988 | 0.72 | ROCK1 (0.42) | PIP4K2APIP4K2BCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL13354456 | 0.70 | PIP4K2A (0.58) | PIP4K2APIP4K2BFYNCYP17A1CYP11B1 | |
| SCHEMBL16269418 | 0.70 | CHRNB2 (0.46) | KDRBRAFVSIR | |
| SCHEMBL15858028 | 0.68 | BRAF (0.50) | KDRBRAF | |
| Trifluoroacetic Acid SCHEMBL3698032 | 0.68 | HTR5A (0.41) | PIP4K2APIP4K2BDYRK1AKDRNPC1 | |
| SCHEMBL3348627 | 0.68 | PIP4K2A (0.54) | PIP4K2APIP4K2BFYNCYP17A1CYP11B1 | |
| SCHEMBL31317869 | 0.67 | CYP11B1 (0.63) | PIP4K2APIP4K2BFYNCYP17A1CYP11B1 | |
| SCHEMBL3708145 | 0.67 | CYP2A6 (0.57) | PIP4K2APIP4K2BFYNCYP17A1CYP11B1 | |
| SCHEMBL13322392 | 0.67 | PIP4K2A (0.54) | PIP4K2APIP4K2BFYNCYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851199-B1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-7625889-B2 | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | HTR2A, HTR2B, HTR2C | PIP4K2A 2895/4885PIP4K2B 3012/4885FYN 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.